On May 14, 2026 Degron Therapeutics ("Degron"), a clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines targeting previously undruggable or insufficiently drugged proteins, reported the closing of a $40 million Series A Extension. The round was led by LAPAM CAPITAL. Additional investors include GTJA Investment Group, Fortune Capital, CSPC & Growth, ApicHope, GF Xinde, CASSTAR, Kinghall Ventures, and GAGE Capital. This brings Degron’s total capital raised to $95 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing will advance Degron’s lead program, DEG6498—a first-in-class HuR (Human antigen R) molecular glue degrader—which entered the clinic in late 2025 with first patient dosed in November. The program, which targets a previously undruggable RNA-binding protein with key roles in driving cancer, inflammation, and metabolic disorders, is currently in dose escalation in a Phase 1 study in patients with advanced solid tumors.

"We are thrilled to welcome this distinguished group of investors who share our vision for transforming the treatment of serious diseases with high unmet need through our innovative MGD platform," said Lily Zou, Ph.D., co-founder and CEO of Degron Therapeutics. "This financing will support the continued advancement of our clinical-stage and preclinical pipeline and further strengthen our technology platform. The strong interest from leading healthcare investors underscores confidence in our approach to developing novel MGDs. With our first-in-class HuR program now advancing in the clinic and two additional immunology programs approaching pre-clinical development, we are making significant progress toward our goal of delivering breakthrough therapies to improve patients’ lives."

Proceeds from this financing will support the continued clinical development of DEG6498, advancing immunology programs to development candidate stage in 2026, and the ongoing expansion of the company’s proprietary GlueXplorer platform to generate potential first-in-class and best-in-disease molecular glue degrader candidates.

"We are pleased to lead this financing round for Degron. Targeted protein degradation remains a key focus for us, and Degron’s proprietary molecular glue platform, built on deep expertise and a strong data foundation, demonstrates robust capabilities in discovering novel targets and compounds, including for historically undruggable targets," said Mr. Zhihua Yu, Chairman of Lapam Capital, which led the financing. "We are impressed by the team’s strengths across R&D, translational development, and business development. With this financing, we believe Degron is well-positioned to advance its pipeline efficiently and generate compelling clinical data to benefit patients."

Founded in 2021 by ShanghaiTech University professor and company co-founder Yong Cang, Ph.D., Degron Therapeutics built a de novo molecular glue degrader discovery platform, GlueXplorer. The company has created more than 10,000 structurally differentiated MGD compounds across more than 150 novel non-IMiDs cores, combined with multiple complementary screening and validation approaches. The platform has enabled Degron to build a pipeline of programs targeting important disease-causing proteins that have historically been inaccessible to conventional small-molecule drugs.

In addition to advancing its internal pipeline, Degron continues to partner with leading pharmaceutical and biotechnology companies to expand MGD R&D across multiple therapeutic areas, including its ongoing collaboration with Takeda.

About DEG6498

DEG6498 is a potent, orally bioavailable small-molecule molecular glue degrader that induces the interaction between the E3 ubiquitin ligase component cereblon (CRBN) and the RNA-binding protein Human antigen R (HuR), leading to the targeted degradation of HuR protein. DEG6498 is being evaluated in a Phase 1 first-in-human study (NCT07244835 / CTR20254261) in patients with advanced solid tumors.

(Press release, Shanghai Degron Therapeutics, MAY 14, 2026, View Source [SID1234665739])

On May 14, 2026 Ontada, a McKesson business dedicated to real-world oncology data and insights, reported that it will present new real‑world research and introduce ON.Journey, a new oncology data solution, at ISPOR 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To continue advancing impactful real-world oncology research, Ontada is launching ON.Journey, a new portfolio of off-the-shelf, longitudinal oncology datasets. Built using oncology-specific artificial intelligence and natural language processing applied to structured and unstructured clinical data from Ontada’s proprietary dataset of electronic medical records from community oncology practices, ON.Journey enables medical affairs, health economics and outcomes research (HEOR), epidemiology, and real-world evidence teams to generate rich clinical insights with speed. With claims data natively integrated, ON.Journey allows teams to analyze treatment utilization alongside clinical outcomes—without the need for custom integration or third-party linkage.

"ON.Journey reflects our focus on delivering data solutions that help life sciences teams generate evidence with greater speed and consistency," said Christine Davis, president of Ontada. "It enables access to research-grade oncology data, supporting evolving needs across the lifecycle."

Ontada will present 12 posters at ISPOR 2026, including four that examine real-world treatment adoption, outcomes and patterns of care across community oncology populations.

"Real‑world evidence provides important insight into how cancer care is delivered," said Jessica K. Paulus, ScD, vice president, Real-World Research for Ontada. "The studies presented at ISPOR reflect our commitment to using high‑quality community oncology data to inform evidence generation and deepen understanding of care delivered in real world clinical practice settings."

Highlights of Ontada’s presence at ISPOR include:

1. Poster #HSD11: Improving Real-World Adoption of HER2-Low Therapies Through Targeted Educational Initiatives

Monday, May 18, 10:30 a.m. – 1:30 p.m. EDT
This observational study and educational initiative evaluates the use of evidence‑based educational outreach in supporting adoption of updated treatment guidelines for HER2‑low therapies.
2. Poster #MSR66: Integrating Generative Artificial Intelligence (AI) into Biostatistical Workflows for Trial Emulation: A Framework to Accelerate Real-World Evidence Generation

Monday, May 18, 4:00 p.m. – 7:00 p.m. EDT
This research outlines a framework for applying generative AI to trial‑emulation workflows to support more scalable and reproducible real‑world evidence generation.
3. Poster # RWD54: Evolution of Homologous Recombination Repair (HRR) Genetic Testing by Race Among Patients with Metastatic Prostate Cancer (mPC) in a Large Community Oncology Setting in the US, 2015 – 2024

Monday, May 18, 4:00 p.m. – 7:00 p.m. EDT
This retrospective, observational analysis uses structured electronic health record data to describe HRR genetic testing patterns by race among patients with metastatic prostate cancer.
4. Poster # HSD112: Real-World Patterns of Homologous Recombination Repair Testing of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in the US Community Oncology Setting

Wednesday, May 20, 9:00 a.m. – 11:30 a.m. EDT
This retrospective, observational cohort study examines real-world patterns of HRR genetic testing among patients, highlighting gaps in testing during earlier stages of advanced disease.
Visit the Ontada Booth (#410) at the Pennsylvania Convention Center from May 18-20 to learn more about ON.Journey and Ontada research and data capabilities.

(Press release, Ontada, MAY 14, 2026, View Source [SID1234665738])

On May 14, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With Lens, Tempus’ AI-enabled analytical platform, BMS and Tempus are applying insights from a vast library of de-identified multimodal records to optimize clinical research and strengthen PTRS across BMS’ development portfolio. This collaboration combines unprecedented scale of real-world data with emerging AI-techniques to pressure test assumptions, characterize complex patient populations, validate control group assumptions, and pinpoint the optimal patient segments most likely to benefit from investigational therapies.

This new initiative is supporting key assets in solid tumor oncology, including lung, colon, and prostate cancers. Beyond oncology, the collaboration extends into neuroscience to accelerate drug development in Alzheimer’s Disease, demonstrating the versatility of the Tempus multimodal database across multiple therapeutic areas.

"Our collaboration with BMS aims to optimize clinical development by peering deeper into patient biology than ever before," said Ryan Fukushima, CEO of Data and Apps at Tempus. "Our multimodal data library allows us to connect the dots between clinical records and molecular subtypes. Together, we are doing more than just generating insights. We are uncovering the hidden biological signals of unmet patient need, which allows us to assess trial assumptions and stratify patient groups with unprecedented precision. We are moving past traditional approaches and creating a new level of data-driven confidence in the drug development process."

"This collaboration is about improving the quality of decisions we make in development, where the impact is greatest," said Bryan Campbell, Senior Vice President, Drug Development Strategy & Innovation at Bristol Myers Squibb. "By combining Tempus’ multimodal real-world data capabilities with our development expertise, we can rigorously pressure-test trial assumptions, better understand patient heterogeneity, and design studies with a higher probability of technical and regulatory success. This is a critical step toward more disciplined, data-driven development with the goal of bringing life-changing medicines to patients faster."

This initiative builds upon the existing work between Tempus and BMS, which includes the deployment of the Next Pathways program across 13 community-based health systems to address care gaps for patients with advanced non-small cell lung cancer (aNSCLC).

(Press release, Tempus, MAY 14, 2026, View Source [SID1234665737])

On May 14, 2026 Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent Corporate Highlights and Upcoming Milestones

INBRX-106
In May 2026, we announced updated interim data from our randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (Combined Positive Score (CPS) ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).
We plan to announce progression-free survival (PFS) data from the randomized Phase 2 trial in HNSCC in combination with pembrolizumab in the fourth quarter of 2026.
ozekibart (INBRX-109)
In April 2026, we announced updated interim data from our Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC);
Additionally, in April 2026, we submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ozekibart in conventional chondrosarcoma; and
We plan to meet with the FDA in the second half of 2026 to discuss plans to initiate a first-line registrational trial in CRC. We also plan to discuss with the FDA the potential for accelerated regulatory pathways for ozekibart in fourth-line colorectal cancer and in refractory Ewing sarcoma.
Financial Results

Cash and Cash Equivalents. As of March 31, 2026, the Company had cash and cash equivalents of $161.7 million, as compared to $124.2 million as of December 31, 2025. The Company’s cash balance increased as a result of the receipt of gross proceeds of $75.0 million in March 2026 upon entering into the First Amendment to the Loan and Security Agreement (March 2026 Amendment) with Oxford Finance LLC (Oxford).
R&D Expense. Research and development expenses were $25.2 million for the first quarter of 2026, as compared to $36.9 million for the first quarter of 2025. This decrease was primarily related to lower clinical trial costs associated with ozekibart for the treatment of unresectable or metastatic conventional chondrosarcoma as the trial approached completion of enrollment, as well as a decrease in contract manufacturing expenses due to the timing and completion of certain manufacturing activities required to support our clinical trials. In addition, personnel-related expenses decreased as a result of a decrease in headcount in the current period.
G&A Expense. General and administrative expenses were $5.7 million during the first quarter of 2026, compared to $6.0 million during the first quarter of 2025. These expenses were consistent in each period with a slight decrease in personnel-related expenses as a result of a decrease in headcount in the current period.
Other Expense, Net. Other expense, net was $2.5 million during the first quarter of 2026, compared to $0.4 million during the first quarter of 2025. The increase reflects higher interest expense following the Company’s receipt of an additional $75.0 million in principal, bringing the outstanding loan balance from $100.0 million to $175.0 million during the first quarter of 2026, as well as lower interest income on the Company’s cash and money market balances reflecting lower average cash balances and a decline in short-term interest rates.
Net Loss. Net loss was $33.4 million during the first quarter of 2026, or $2.15 per share, basic and diluted, as compared to a net loss of $43.3 million during the first quarter of 2025, or $2.80 per share, basic and diluted.

(Press release, Inhibrx, MAY 14, 2026, View Source [SID1234665736])

On May 14, 2026 SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, reported that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer agent, in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This multi-center trial, conducted across sites globally including the United States and Europe, will enroll up to 135 patients. The study is designed in three sequential stages: a Phase 1b dose-escalation phase using a 3+3 design to determine the Maximum Tolerated Dose (MTD) at dose levels of 50–70 mg/m², followed by a two-part Phase 2 consisting of Phase 2a and Phase 2b. Phase 2a will conduct dose optimization to identify the optimal therapeutic dose, after which Phase 2b will proceed with dose expansion at the optimized dose to further evaluate clinical activity across a broader patient population. Across Phase 2, key efficacy endpoints including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) will be assessed to generate the clinical evidence necessary to support regulatory review process.

The advancement into Phase 2 is supported by encouraging prior Phase 1 results conducted in Korea, in which SNB-101 demonstrated a favorable safety profile with no Grade 3 or higher diarrhea events, a disease control rate (DCR) of 83.3% in high-dose cohorts, and a mean progression-free survival (PFS) of 6.3 months in SCLC patients. These findings compare favorably with outcomes historically reported for currently available later-line treatment options, including Zepzelca and Topotecan.

Based on its Phase 1 results, SNB-101 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for SCLC. Together with Orphan Drug Designation from the FDA and EMA, these designations reflect that SNB-101 has fully established the regulatory framework necessary to pursue accelerated approval.

As a monotherapy, SNB-101 has demonstrated encouraging clinical activity together with a favorable tolerability profile in previously treated SCLC patients. The company believes these findings support the continued clinical development of SNB-101 as a potential treatment option for patients with relapsed SCLC, particularly in later-line settings where tolerability and efficacy remain an important unmet need.

In parallel with the ongoing monotherapy program, SN BioScience is actively expanding the development of SNB-101 into combination strategies with immunotherapy agents (including anti-PD-1, anti-PD-L1, and DLL3-targeted BiTE T-cell engager therapies) currently used in standard SCLC treatment. The company has already obtained EMA approval for a clinical study evaluating SNB-101 in combination with one immunotherapy agent and is planning to submit an additional CTA within this year for a separate study involving another immunotherapy combination.

In addition, SN BioScience is pursuing the expansion of SNB-101 into additional solid tumor indications, including gastric and pancreatic cancers, through ongoing collaborations and strategic discussions with global pharmaceutical companies.

(Press release, SN BioScience, MAY 14, 2026, View Source [SID1234665735])